Nexus receives FDA approval for Emerphed syringes

LINCOLNSHIRE - Nexus Pharmaceuticals Inc. said it has received U.S. Food and Drug Administration approval of the drug Emerphed administered using various sizes of its single-dose, pre-filled syringes.

Emerphed is used for the treatment of hypotension occurring in the setting of anesthesia, the company said.

"These patented products showcase Nexus' ability to provide innovative therapies that address clinicians' concerns about delivering efficient and safe medications," said Usman Ahmed, Nexus chief executive officer and president.

Nexus received FDA approval for Emerphed (ephedrine sulfate) injection in a ready-to-use vial in April 2020. A patent covering certain applications of Emerphed Ready-to-Use Ephedrine Sulfate Injection was issued by the U.S. Patent and Trademark Office in August 2021. Nexus has since earned several additional patents on its Emerphed line of vials and syringes and continues to pursue further parent protection related to Emerphed, the company said.